Objective To explore clinical effect of Liuwei Nengxiao Capsules combined with lansoprazole and mosapride in treatment of reflux esophagitis. Methods Patients （92 cases） with reflux esophagitis in Shandan People＇s Hospital from April 2014 to April 2015 were randomly divided into the control and treatment groups, and each group had 46 eases. The patients in the control group were po administered with Lansoprazole Enteric-coated Tablets after meals in the morning, 1 tablet/time, once daily. And they were po administered with Mosapride Citrate Tablets after meals, 1 tablet/time, three times daily. The patients in the treatment group were po administered with Liuwei Nengxiao Capsules after meals on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 8 weeks and reviewed once every 4 weeks. After treatment, the clinical efficacy, main symptom scores and adverse reaction in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 71.74% and 86.96%, respectively, and there were differences between two groups （P 〈 0.05）. After treatment for 2, 4, and 8 weeks, symptom scores in two groups were significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. And the improvement of clinical symptom in treatment group treated for 8 weeks was better than that in the control group, with significant difference between two groups （P 〈 0.05）. There was no significant difference in adverse reactions rate between two groups. Conclusion Liuwei Nengxiao Capsules combined with lansoprazole and mosapdde has a significant clinical effect in treatment of reflux esophagitis, can obviously inhibited the secretion of gastric acid, which has a certain clinical application value.
Liuwei Nengxiao Capsules
Lansoprazole Enteric-coated Tablets
Mosapride Citrate Tablets